

DOXYLAMINE/PYRIDOXINE tablets (Xonvea® ▼) for Nausea and Vomiting in Pregnancy

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of DOXYLAMINE/PYRIDOXINE tablets (Xonvea® ▼) for the treatment of nausea and vomiting in pregnancy.

GREY

Doxylamine/Pyridoxine (Xonvea®) is a new preparation that provides the action of two unrelated compounds. Doxylamine succinate (an antihistamine) and pyridoxine hydrochloride (vitamin B6) provide anti-nauseant and antiemetic activity. (1)

This recommendation will be reviewed within 6 months of the product launch in the UK market, following a full assessment of the evidence by the New Medicines Sub Group.

In the meantime, prescribers should continue to follow current national guidance for treatment of nausea and vomiting in pregnancy: [Nausea/vomiting in pregnancy - NICE CKS](#) (last updated June 2017)

References

1. Alliance Pharmaceuticals. Summary of Product Characteristics - Xonvea 10 mg/10 mg gastro-resistant tablets; 01 October 2018. Accessed 17 October 2018 at: <https://www.medicines.org.uk/emc/product/9344>

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.